Dr. Vijay Chhajlani is Chief Technology Officer at ModeX and has more than 25 years of experience in the pharmaceutical industry, with extensive knowledge of discovery and development of small molecule as well as protein therapeutics. Most recently, Vijay was Vice President within the Product Development and Technical Operations group at Jounce Therapeutics, where he played a CMC leadership role in gene to cGMP manufacturing of several clinical candidates. Prior to Jounce, Vijay held positions of increasing leadership at Shire Pharmaceuticals and Bristol Myers Squibb for process and analytical development of complex biologics for late phase development and commercialization. Ahead of his time spent in biologics CMC work, Vijay led the small molecule Hit to Lead programs in cardiovascular, metabolic and neuroscience therapy areas at AstraZeneca in Sweden and USA.
Vijay earned his Ph.D. in biochemistry from the Cancer Research Institute at Bombay University, India. He completed his pharmacology fellowship from Johns Hopkins University and conducted independent research serving as Associate Professor at Uppsala University, Sweden. He is credited with more than 50 peer reviewed scientific publications and several patents, most notably for the discovery of Melanocortin 1 receptor gene.